Posts

Hydroxyurea FDA approved for the reduction in frequency of painful crises and blood transfusions in paediatric sickle cell anemia patients

On 21 December the FDA granted regular approval to hydroxyurea (Siklos®, Addmedica) for the reduction in frequency of painful crises and the need for blood transfusions in paediatric sickle cell anaemia patients ≥2 years of age with recurrent moderate to severe painful crises.